Table 1.

Summary of the number of high-quality urine and plasma samples per visit and treatment group available for ¹H NMR spectrometry measurements

		Run-in (V1)		Run-in (V2)		Post 2 week (V3)		Post 6 week (V5)
Treatment	Group	Urine	Plasma	Urine	Plasma	Urine	Plasma	Urine	Plasma
Placebo	DF	4	6	4	5	4	1	3	3
Placebo	HF	4	4	4	4	4	NA	4	4
Placebo	DM	4	5	4	5	4	2	2	2
Placebo	HM	4	4	4	4	4	NA	4	4
RSG	DF	4	2	4	4	4	1	3	3
RSG	HF	4	4	4	3	4	NA	4	4
RSG	DM	4	4	4	4	4	1	3	3
RSG	HM	4	4	4	4	4	NA	4	4

Plasma samples collected on visit 3 (2-weeks post) were measured only if no sample was available at visit 5 (last observation carried forward). DF, Diabetic female; HF, healthy female; DM, diabetic male; HM, healthy male; RSG, rosiglitazone; Vx, visit x; NA, not analysed.